Ruxolitinib is an oral, selective JAK1/JAK2 inhibitor with clinical activity in hemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome with a macrophage‐derived cytokine profile similar to that observed in COVID‐19 [5, 6, 7]. Here, JAK1 is linked to COVID-19.